Treating rheumatic diseases in pregnancy: Dos and don'ts

Annals of the Rheumatic Diseases

Volumn 65, Issue SUPPL. 3, 2006, Pages

  Lockshin, M D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL FACTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEUPRORELIN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TSUKUBAENOLIDE;

CONFERENCE PAPER; DRUG INFORMATION; DRUG SAFETY; DRUG USE; FEMALE INFERTILITY; FERTILITY; GESTATIONAL AGE; HUMAN; INTERVENTION STUDY; KIDNEY DISEASE; MALE INFERTILITY; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PREGNANCY; PREGNANCY DISORDER; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; REPRODUCTION; RHEUMATIC DISEASE; TERATOGENESIS; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; INFERTILITY; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RHEUMATIC DISEASES;

EID: 33750296915     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.058420     Document Type: Conference Paper

References (11)

1. Swan SH. Intrauterine exposure to diethylstilbestrol: long-term effects in humans. APMIS 2000;108:793-804.
2. Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003;157:397-402.
3. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Antirheumatic drug therapy and reproduction. 2006;8:209.
4. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arthritis Rheum 2005;52:2761-7.
5. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-0.
6. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
7. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8.
8. Hyrich K, Symmons D, Watson K, Silman A. Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum 2006 (in press).
9. Chambers C, Johnson D, Jones K. Pregnancy outcome in women exposed to anti-TNF-alpha medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum 2004;50:S479-S480.
10. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:485.
11. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006;43:68-77.